NCT01059812已完成3 期
A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™: INTENSIFY ALL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 424
- 试验地点
- 1
- 主要终点
- Change in HbA1c (Glycosylated Haemoglobin) After 26 Weeks of Treatment
研究概览
简要总结
This trial is conducted in Asia. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with biphasic insulin aspart (BIAsp) 30 in patients with type 2 diabetes not optimally controlled on once or twice daily insulin with or without metformin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female at least 18 years of age (at least 20 years for Japan)
- •Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months
- •Subject on basal human or analogue insulin, once daily (OD) or twice daily (BID) with or without metformin for at least 3 months or subject on premixed human or analogue insulin or self-mixed insulin regimen, containing 20-40% fast/rapid-acting component, OD or BID, with or without metformin, for at least 3 months
- •HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis
- •Body mass index (BMI) maximum 35.0 kg/m^2
排除标准
- •Treatment with oral antidiabetic drugs (OADs) (except metformin) within the last 8 weeks prior to Visit 1
- •Treatment with thiazolidinediones (TZDs) or glucagon like peptide 1 (GLP-1) receptor agonists within 3 months prior to Visit 1
- •Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
- •Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)
- •Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements
- •Cancer and medical history of cancer (except basal cell skin cancer or squamous cell skin cancer)
研究组 & 干预措施
IDegAsp BID
Experimental
干预措施: insulin degludec/insulin aspart (Drug)
BIAsp 30 BID
Active Comparator
干预措施: biphasic insulin aspart 30 (Drug)
结局指标
主要结局
Change in HbA1c (Glycosylated Haemoglobin) After 26 Weeks of Treatment
时间窗: Week 0, Week 26
Change from baseline in HbA1c after 26 weeks of treatment.
次要结局
- Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26(Week 26)
- Rate of Confirmed Hypoglycaemic Episodes(Week 0 to Week 26 + 7 days follow up)
- Change in Body Weight(Week 0, Week 26)
- Rate of Nocturnal Confirmed Hypoglycaemic Episodes(Week 0 to Week 26 + 7 days follow up)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01059799Novo Nordisk A/S435
已完成
3 期
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)DiabetesDiabetes Mellitus, Type 2NCT03175120Novo Nordisk A/S453
已完成
3 期
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)Diabetes Mellitus, Type 2DiabetesNCT03172494Novo Nordisk A/S720
已完成
3 期
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic DrugsDiabetesDiabetes Mellitus, Type 2NCT02911948Novo Nordisk A/S210
已完成
3 期
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT02762578Novo Nordisk A/S543